128298-28-2
128298-28-2
Chemical Structure
Remacemide
Synonym(s): FPL 12924; PR 934-423; FPL 13592
- CAS No.: 128298-28-2
- Formula:C17H20N2O
- Molecular Weight:268.35
InChIKey: YSGASDXSLKIKOD-UHFFFAOYSA-N
SMILES: O=C(CN)NC(C)(CC1=CC=CC=C1)C2=CC=CC=C2
Biological Activity: Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neuroprotection activity in animal models of hypoxia and ischemic stroke. Remacemide is also an anticonvulsant, and can be used in Parkinson's disease and Huntington's disease research[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Remacemide | Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neuroprotection activity in animal models of hypoxia and ischemic stroke. Remacemide is also an anticonvulsant, and can be used in Parkinson's disease and Huntington's disease research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Schachter SC, et al. Remacemide: current status and clinical applications. Expert Opin Investig Drugs. 2000 Apr;9(4):871-83. [Content Brief]
- [2]. Dyker AG, et al. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke. 1999 Sep;30(9):1796-801. [Content Brief]
- [3]. Greenamyre JT, et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol. 1994 Jun;35(6):655-61. [Content Brief]
- [4]. Kieburtz K, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord. 1996 May;11(3):273-7. [Content Brief]
Keywords
